- Home
- IXHL vs NSPR Comparison
IXHL vs NSPR Comparison
Compare IXHL & NSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IXHL
- NSPR
- Stock Information
- Founded
- IXHL 2001
- NSPR 2005
- Country
- IXHL Australia
- NSPR United States
- Employees
- IXHL N/A
- NSPR N/A
- Industry
- IXHL
- NSPR Medical/Dental Instruments
- Sector
- IXHL
- NSPR Health Care
- Exchange
- IXHL Nasdaq
- NSPR Nasdaq
- Market Cap
- IXHL 78.7M
- NSPR 74.8M
- IPO Year
- IXHL N/A
- NSPR N/A
- Fundamental
- Price
- IXHL $0.38
- NSPR $2.50
- Analyst Decision
- IXHL
- NSPR Strong Buy
- Analyst Count
- IXHL 0
- NSPR 2
- Target Price
- IXHL N/A
- NSPR $4.50
- AVG Volume (30 Days)
- IXHL 178.1M
- NSPR 109.7K
- Earning Date
- IXHL 09-29-2025
- NSPR 08-05-2025
- Dividend Yield
- IXHL N/A
- NSPR N/A
- EPS Growth
- IXHL N/A
- NSPR N/A
- EPS
- IXHL N/A
- NSPR N/A
- Revenue
- IXHL $98,000.00
- NSPR $7,066,000.00
- Revenue This Year
- IXHL $2,538.49
- NSPR $4.85
- Revenue Next Year
- IXHL $249.95
- NSPR $113.47
- P/E Ratio
- IXHL N/A
- NSPR N/A
- Revenue Growth
- IXHL N/A
- NSPR 7.60
- 52 Week Low
- IXHL $0.08
- NSPR $1.99
- 52 Week High
- IXHL $3.12
- NSPR $3.80
- Technical
- Relative Strength Index (RSI)
- IXHL 44.52
- NSPR 51.38
- Support Level
- IXHL $0.34
- NSPR $2.37
- Resistance Level
- IXHL $0.57
- NSPR $2.60
- Average True Range (ATR)
- IXHL 0.13
- NSPR 0.19
- MACD
- IXHL -0.05
- NSPR -0.01
- Stochastic Oscillator
- IXHL 4.09
- NSPR 25.86
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
About NSPR InspireMD Inc.
InspireMD Inc is a United States based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System (MGuard Prime EPS). It generates the majority of the revenue from the sales of CGuard EPS which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The group operates in Italy, Germany, Russia and other countries.